Stockreport

Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp [Yahoo! Finance]

Moringa Acquisition Corp - Class A Ordinary Shares  (MACA) 
PDF In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Isra [Read more]